Evidence map›Paper›PMID 40916045›Full record

ArticleObesity (Silver Spring, Md.)2025

Tirzepatide for the Maintenance of Body Weight Reduction: Rationale, Design, and Baseline Characteristics of SURMOUNT-MAINTAIN.

Deborah B Horn, Louis J Aronne, Sean Wharton, Harold E Bays, Elisa Gomez-Valderas, Avigdor D Arad, Palash Sharma, Julia P Dunn, Cagri Senyucel, Clare J Lee

Registry-linked trialAbstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in Obesity (Silver Spring, Md.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT06047548. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06047548 phase3completed

A Phase 3b, Randomized Controlled Study to Evaluate the Efficacy and Safety of Tirzepatide Once Weekly 5 mg and/or Maximum Tolerated Dose Versus Placebo for Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (SURMOUNT-MAINTAIN)

Ran2023Enrolled441Registered outcomes8Posted comparisons0ConditionsObesity, OverweightArmsPlacebo, Tirzepatide
Open the trial in the graph
3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Deborah B HornUniversity of Texas Center for Obesity Medicine and Metabolic Performance, Department of Surgery, University of Texas McGovern Medical School, Houston, Texas, USA.
Louis J AronneComprehensive Weight Control Center, Division of Endocrinology, Diabetes & Metabolism, Weill Cornell Medicine, New York, New York, USA.ORCID https://orcid.org/0000-0002-9890-9401
Sean WhartonUniversity of Toronto and Wharton Weight Management Clinic, Toronto, Ontario, Canada.ORCID https://orcid.org/0000-0003-0111-1530
Harold E BaysLouisville Metabolic and Atherosclerosis Research Center, Louisville, Kentucky, USA.ORCID https://orcid.org/0000-0001-9912-1408
Elisa Gomez-ValderasEli Lilly and Company, Indianapolis, Indiana, USA.
Avigdor D AradEli Lilly and Company, Indianapolis, Indiana, USA.
Palash SharmaEli Lilly and Company, Indianapolis, Indiana, USA.
Julia P DunnEli Lilly and Company, Indianapolis, Indiana, USA.ORCID https://orcid.org/0000-0001-9561-0183
Cagri SenyucelEli Lilly and Company, Indianapolis, Indiana, USA.
Clare J LeeEli Lilly and Company, Indianapolis, Indiana, USA.

Funding

Eli Lilly and Company
6 · The paper itself

Abstract

objectiveSURMOUNT-MAINTAIN aims to evaluate the efficacy and safety of reducing the tirzepatide dose and/or continuing the maximum tolerated dose (MTD) versus placebo in maintaining body weight (BW) reduction achieved with tirzepatide MTD.

methodsThis Phase 3b, multicenter, randomized, parallel-arm, double-blinded, placebo-controlled, 52-week clinical trial is in progress comparing treatment with once weekly tirzepatide (5 mg and/or MTD of 15 mg or 10 mg) versus placebo in achieving BW reduction maintenance from the initial 60-week open-label weight-loss period on tirzepatide MTD, in adults with obesity (BMI ≥ 30 kg/m

resultsParticipants are mostly female (65%) with a mean ± SD age of 47 ± 13 years, BW 114 ± 27 kg, BMI 40 ± 8 kg/m

conclusionsThe SURMOUNT-MAINTAIN trial will evaluate whether reducing or continuing the tirzepatide dose as a long-term treatment option may help maintain the reduced BW initially achieved with tirzepatide MTD versus switching to placebo. Combined, this study may provide additional evidence to help tailor patient-centered strategies for maintenance of BW reduction in adults living with obesity.

trial registrationClinicalTrials.gov identifier: NCT06047548.

Indexed as

Anti-Obesity AgentsObesityWeight LossAdultBody Mass IndexClinical Trials, Phase III as TopicDouble-Blind MethodFemaleHumansMaleMaximum Tolerated DoseMiddle AgedMulticenter Studies as TopicRandomized Controlled Trials as TopicTirzepatideTreatment OutcomeAnti-Obesity AgentsTirzepatideantiobesity medicationobesityobesity management medicationSURMOUNT‐MAINTAINtirzepatide

Identifiers

PMID40916045
PMCPMC12477106

What OpenQuestion holds

Texttitle and abstract
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.